Displaying 13 - 24 of 55
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: Quantitative hepatitis B surface antigen today and tomorrow (Complete Session) - EASL Congress 2024

View
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Displaying 13 - 24 of 55